By SPC News Staff
The FDA approved inclisiran (Leqvio, Novartis) to reduce low-density lipoprotein cholesterol (LDL-C) with two doses per year, after an initial dose and one at three months.
Inclisiran, a first-in-class small interfering RNA (siRNA), is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with clinical atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) whose LDL-C is not lowered